Using blood tests to assess early treatment response in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of circulating tumor DNA (ctDNA) in detecting early treatment responses in patients with various solid tumors, including prostate, head and neck, esophageal, and genitourinary cancers. By identifying molecular residual disease (MRD) through ctDNA analysis, the study seeks to enhance cancer diagnosis, treatment, and surveillance, ultimately guiding clinical decision-making in personalized medicine. The findings could pave the way for future interventional trials that escalate therapy based on early ctDNA detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Eligible healthy donors will be at least 18 years of age.

Exclusion Criteria:

* Healthy donors younger than 18 years of age

Where it's running

• Washington University School of Medicine
  St Louis, Missouri, United States Recruiting

Study contacts

• Principal investigator: Melissa Reimers, M.D. — Washington University School of Medicine
• Study coordinator: Melissa Reimers, M.D.
• Email: cbumb@wustl.edu
• Phone: 314-362-7249

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A resource for collecting cancer data and biospecimens

  This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.

  Recruiting at 42 sites University of Nebraska · Greenwood Village, Colorado and 41 other locations · NCT02012699

• Virtual exercise program to preserve function and prevent disability during chemotherapy

  This trial tests whether supervised resistance sessions by video plus short home aerobic workouts help adults 18–64 maintain strength and stay active while receiving curative-intent chemotherapy.

  Recruiting at 29 sites Alliance for Clinical Trials in Oncology · Dublin, California and 29 other locations · NCT07059884

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Using Riluzole to Help Breast Cancer Survivors with Cognitive Issues

  This study is testing if the medication riluzole can help breast cancer survivors who are having trouble with thinking and memory feel better.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06580002

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.